Sanofi Acquires Vigil Neuroscience for $470 Million, Bolstering Alzheimer’s Drug Pipeline

Sanofi will acquire Vigil Neuroscience for approximately $470 million upfront, with Vigil shareholders also eligible for contingent future payments if the Alzheimer’s drug candidate VG-3927 is commercialized2 5.

VG-3927, Vigil’s lead program, is an oral small-molecule TREM2 agonist designed to activate microglia—the brain's immune cells—and improve their neuroprotective function in Alzheimer's disease2 3 5.

The acquisition will add VG-3927 to Sanofi’s neurology portfolio, marking the company’s first pipeline entry for Alzheimer’s and expanding its reach in neurodegenerative disease R&D1 3.

VG-3927 has completed a Phase 1 study demonstrating safety and CNS penetration, with Phase 2 clinical testing in Alzheimer’s slated to start in the third quarter of 20252 5.

The deal follows Sanofi’s previous $40 million investment in Vigil and is part of a larger strategic pivot toward neurodegenerative diseases, an area where Sanofi has recently formed multiple partnerships1 3.

The transaction excludes Vigil’s monoclonal antibody program VGL101, which will revert to Amgen prior to closing3 5.

The move reflects Sanofi’s confidence in next-generation Alzheimer’s targets after setbacks in the field, reinforcing its commitment to innovative neuroscience therapies4 1.